Blood endocan as a biomarker for breast cancer recurrence
Endocan was reported to affect breast cancer patients negatively and was able to be detected from patients' blood. This study aimed to investigate if the measurement of blood endocan in breast cancer patients with high ESM1 expression could be an effective tool to detect postoperative recurrenc...
Gespeichert in:
| Veröffentlicht in: | Cancer biomarkers : section A of Disease markers 2024-01, Vol.41 (2), p.145-154 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 154 |
|---|---|
| container_issue | 2 |
| container_start_page | 145 |
| container_title | Cancer biomarkers : section A of Disease markers |
| container_volume | 41 |
| creator | Daiki, Kentaro Kanada, Yoko Nagata, Aya Taruno, Kanae Igarashi, Katsuhide Yamochi, Toshiko Ota, Hirotaka Sato, Fumiaki Nakamura, Seigo Kato, Yoshinori |
| description | Endocan was reported to affect breast cancer patients negatively and was able to be detected from patients' blood.
This study aimed to investigate if the measurement of blood endocan in breast cancer patients with high ESM1 expression could be an effective tool to detect postoperative recurrence compared with existing tumor markers.
Blood was collected before and after the tumor resection from the mouse models of breast cancer, and endocan levels were measured while visualizing metastatic recurrence with noninvasive luminescence imaging. In clinical settings, blood was withdrawn from 16 breast cancer patients before and after the tumor resection, and the effect of lumpectomy on blood endocan level was evaluated. Additionally, the blood endocan from 20 patients diagnosed with postoperative recurrence was measured, and their positivity rate for endocan was compared with that for serum carcinoembryonic antigen (CEA) or cancer antigen 15-3 (CA15-3).
Our preclinical and clinical experiments revealed that blood endocan levels reflected tumor burden. Furthermore, over 60% of patients suffering from postoperative recurrence who tested negative for CEA or CA15-3 were positive for endocan.
Our results support the clinical significance of endocan in breast cancer patients for detecting breast cancer recurrence. |
| doi_str_mv | 10.3233/CBM-240034 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11495321</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3110407768</sourcerecordid><originalsourceid>FETCH-LOGICAL-c260t-ccccc8b28b272fe5ceb07441ae1260908871672c73806e853e5ba8080bf339e3</originalsourceid><addsrcrecordid>eNpdkUtLAzEUhYMotj42_gAZcCPCaJKbTJKVaPEFihv3IZPe0dHppCYdwX9vSquoIZBLzsfhXA4hB4yeAgc4m1w-lFxQCmKDjJlWstTS8M08SyVKyiSMyE5Kr5QKYNxskxEYAEYNHxNz2YUwLbCfBu_6wqXCFXUbZi6-YSyaEIs6okuLIqs-_0T0Q4yY5z2y1bgu4f763SVP11dPk9vy_vHmbnJxX3pe0UXpl0fXPF_FG5Qea6qEYA5Z1g3VWrFKca9A0wq1BJS101TTugEwCLvkfGU7H-oZTj32i-g6O49tzvhpg2vtX6VvX-xz-LCMCSOBs-xwvHaI4X3AtLCzNnnsOtdjGJIFxqigSlU6o0f_0NcwxD6vt6Sk0NzoKlMnK8rHkFLE5icNo3bZiM2N2FUjGT78nf8H_a4AvgD4CoSR</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3115482986</pqid></control><display><type>article</type><title>Blood endocan as a biomarker for breast cancer recurrence</title><source>MEDLINE</source><source>Sage Journals GOLD Open Access 2024</source><creator>Daiki, Kentaro ; Kanada, Yoko ; Nagata, Aya ; Taruno, Kanae ; Igarashi, Katsuhide ; Yamochi, Toshiko ; Ota, Hirotaka ; Sato, Fumiaki ; Nakamura, Seigo ; Kato, Yoshinori</creator><creatorcontrib>Daiki, Kentaro ; Kanada, Yoko ; Nagata, Aya ; Taruno, Kanae ; Igarashi, Katsuhide ; Yamochi, Toshiko ; Ota, Hirotaka ; Sato, Fumiaki ; Nakamura, Seigo ; Kato, Yoshinori</creatorcontrib><description>Endocan was reported to affect breast cancer patients negatively and was able to be detected from patients' blood.
This study aimed to investigate if the measurement of blood endocan in breast cancer patients with high ESM1 expression could be an effective tool to detect postoperative recurrence compared with existing tumor markers.
Blood was collected before and after the tumor resection from the mouse models of breast cancer, and endocan levels were measured while visualizing metastatic recurrence with noninvasive luminescence imaging. In clinical settings, blood was withdrawn from 16 breast cancer patients before and after the tumor resection, and the effect of lumpectomy on blood endocan level was evaluated. Additionally, the blood endocan from 20 patients diagnosed with postoperative recurrence was measured, and their positivity rate for endocan was compared with that for serum carcinoembryonic antigen (CEA) or cancer antigen 15-3 (CA15-3).
Our preclinical and clinical experiments revealed that blood endocan levels reflected tumor burden. Furthermore, over 60% of patients suffering from postoperative recurrence who tested negative for CEA or CA15-3 were positive for endocan.
Our results support the clinical significance of endocan in breast cancer patients for detecting breast cancer recurrence.</description><identifier>ISSN: 1574-0153</identifier><identifier>ISSN: 1875-8592</identifier><identifier>EISSN: 1875-8592</identifier><identifier>DOI: 10.3233/CBM-240034</identifier><identifier>PMID: 39331092</identifier><language>eng</language><publisher>Netherlands: IOS Press BV</publisher><subject>Adult ; Aged ; Animal models ; Animals ; Antigens ; Biomarkers ; Biomarkers, Tumor - blood ; Blood ; Blood levels ; Breast cancer ; Breast Neoplasms - blood ; Breast Neoplasms - diagnosis ; Breast Neoplasms - pathology ; Breast Neoplasms - surgery ; Carcinoembryonic antigen ; Cell Line, Tumor ; Female ; Humans ; Lumpectomy ; Metastases ; Mice ; Middle Aged ; Mucin-1 - blood ; Neoplasm Proteins - blood ; Neoplasm Recurrence, Local - blood ; Neoplasm Recurrence, Local - diagnosis ; Neoplasm Recurrence, Local - pathology ; Proteoglycans - blood ; Tumor markers ; Tumors</subject><ispartof>Cancer biomarkers : section A of Disease markers, 2024-01, Vol.41 (2), p.145-154</ispartof><rights>Copyright IOS Press BV 2024</rights><rights>2024 – The authors. Published by IOS Press. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c260t-ccccc8b28b272fe5ceb07441ae1260908871672c73806e853e5ba8080bf339e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27915,27916</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39331092$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Daiki, Kentaro</creatorcontrib><creatorcontrib>Kanada, Yoko</creatorcontrib><creatorcontrib>Nagata, Aya</creatorcontrib><creatorcontrib>Taruno, Kanae</creatorcontrib><creatorcontrib>Igarashi, Katsuhide</creatorcontrib><creatorcontrib>Yamochi, Toshiko</creatorcontrib><creatorcontrib>Ota, Hirotaka</creatorcontrib><creatorcontrib>Sato, Fumiaki</creatorcontrib><creatorcontrib>Nakamura, Seigo</creatorcontrib><creatorcontrib>Kato, Yoshinori</creatorcontrib><title>Blood endocan as a biomarker for breast cancer recurrence</title><title>Cancer biomarkers : section A of Disease markers</title><addtitle>Cancer Biomark</addtitle><description>Endocan was reported to affect breast cancer patients negatively and was able to be detected from patients' blood.
This study aimed to investigate if the measurement of blood endocan in breast cancer patients with high ESM1 expression could be an effective tool to detect postoperative recurrence compared with existing tumor markers.
Blood was collected before and after the tumor resection from the mouse models of breast cancer, and endocan levels were measured while visualizing metastatic recurrence with noninvasive luminescence imaging. In clinical settings, blood was withdrawn from 16 breast cancer patients before and after the tumor resection, and the effect of lumpectomy on blood endocan level was evaluated. Additionally, the blood endocan from 20 patients diagnosed with postoperative recurrence was measured, and their positivity rate for endocan was compared with that for serum carcinoembryonic antigen (CEA) or cancer antigen 15-3 (CA15-3).
Our preclinical and clinical experiments revealed that blood endocan levels reflected tumor burden. Furthermore, over 60% of patients suffering from postoperative recurrence who tested negative for CEA or CA15-3 were positive for endocan.
Our results support the clinical significance of endocan in breast cancer patients for detecting breast cancer recurrence.</description><subject>Adult</subject><subject>Aged</subject><subject>Animal models</subject><subject>Animals</subject><subject>Antigens</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - blood</subject><subject>Blood</subject><subject>Blood levels</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - blood</subject><subject>Breast Neoplasms - diagnosis</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - surgery</subject><subject>Carcinoembryonic antigen</subject><subject>Cell Line, Tumor</subject><subject>Female</subject><subject>Humans</subject><subject>Lumpectomy</subject><subject>Metastases</subject><subject>Mice</subject><subject>Middle Aged</subject><subject>Mucin-1 - blood</subject><subject>Neoplasm Proteins - blood</subject><subject>Neoplasm Recurrence, Local - blood</subject><subject>Neoplasm Recurrence, Local - diagnosis</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Proteoglycans - blood</subject><subject>Tumor markers</subject><subject>Tumors</subject><issn>1574-0153</issn><issn>1875-8592</issn><issn>1875-8592</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkUtLAzEUhYMotj42_gAZcCPCaJKbTJKVaPEFihv3IZPe0dHppCYdwX9vSquoIZBLzsfhXA4hB4yeAgc4m1w-lFxQCmKDjJlWstTS8M08SyVKyiSMyE5Kr5QKYNxskxEYAEYNHxNz2YUwLbCfBu_6wqXCFXUbZi6-YSyaEIs6okuLIqs-_0T0Q4yY5z2y1bgu4f763SVP11dPk9vy_vHmbnJxX3pe0UXpl0fXPF_FG5Qea6qEYA5Z1g3VWrFKca9A0wq1BJS101TTugEwCLvkfGU7H-oZTj32i-g6O49tzvhpg2vtX6VvX-xz-LCMCSOBs-xwvHaI4X3AtLCzNnnsOtdjGJIFxqigSlU6o0f_0NcwxD6vt6Sk0NzoKlMnK8rHkFLE5icNo3bZiM2N2FUjGT78nf8H_a4AvgD4CoSR</recordid><startdate>20240101</startdate><enddate>20240101</enddate><creator>Daiki, Kentaro</creator><creator>Kanada, Yoko</creator><creator>Nagata, Aya</creator><creator>Taruno, Kanae</creator><creator>Igarashi, Katsuhide</creator><creator>Yamochi, Toshiko</creator><creator>Ota, Hirotaka</creator><creator>Sato, Fumiaki</creator><creator>Nakamura, Seigo</creator><creator>Kato, Yoshinori</creator><general>IOS Press BV</general><general>IOS Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20240101</creationdate><title>Blood endocan as a biomarker for breast cancer recurrence</title><author>Daiki, Kentaro ; Kanada, Yoko ; Nagata, Aya ; Taruno, Kanae ; Igarashi, Katsuhide ; Yamochi, Toshiko ; Ota, Hirotaka ; Sato, Fumiaki ; Nakamura, Seigo ; Kato, Yoshinori</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c260t-ccccc8b28b272fe5ceb07441ae1260908871672c73806e853e5ba8080bf339e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Animal models</topic><topic>Animals</topic><topic>Antigens</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - blood</topic><topic>Blood</topic><topic>Blood levels</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - blood</topic><topic>Breast Neoplasms - diagnosis</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - surgery</topic><topic>Carcinoembryonic antigen</topic><topic>Cell Line, Tumor</topic><topic>Female</topic><topic>Humans</topic><topic>Lumpectomy</topic><topic>Metastases</topic><topic>Mice</topic><topic>Middle Aged</topic><topic>Mucin-1 - blood</topic><topic>Neoplasm Proteins - blood</topic><topic>Neoplasm Recurrence, Local - blood</topic><topic>Neoplasm Recurrence, Local - diagnosis</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Proteoglycans - blood</topic><topic>Tumor markers</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Daiki, Kentaro</creatorcontrib><creatorcontrib>Kanada, Yoko</creatorcontrib><creatorcontrib>Nagata, Aya</creatorcontrib><creatorcontrib>Taruno, Kanae</creatorcontrib><creatorcontrib>Igarashi, Katsuhide</creatorcontrib><creatorcontrib>Yamochi, Toshiko</creatorcontrib><creatorcontrib>Ota, Hirotaka</creatorcontrib><creatorcontrib>Sato, Fumiaki</creatorcontrib><creatorcontrib>Nakamura, Seigo</creatorcontrib><creatorcontrib>Kato, Yoshinori</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer biomarkers : section A of Disease markers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Daiki, Kentaro</au><au>Kanada, Yoko</au><au>Nagata, Aya</au><au>Taruno, Kanae</au><au>Igarashi, Katsuhide</au><au>Yamochi, Toshiko</au><au>Ota, Hirotaka</au><au>Sato, Fumiaki</au><au>Nakamura, Seigo</au><au>Kato, Yoshinori</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Blood endocan as a biomarker for breast cancer recurrence</atitle><jtitle>Cancer biomarkers : section A of Disease markers</jtitle><addtitle>Cancer Biomark</addtitle><date>2024-01-01</date><risdate>2024</risdate><volume>41</volume><issue>2</issue><spage>145</spage><epage>154</epage><pages>145-154</pages><issn>1574-0153</issn><issn>1875-8592</issn><eissn>1875-8592</eissn><abstract>Endocan was reported to affect breast cancer patients negatively and was able to be detected from patients' blood.
This study aimed to investigate if the measurement of blood endocan in breast cancer patients with high ESM1 expression could be an effective tool to detect postoperative recurrence compared with existing tumor markers.
Blood was collected before and after the tumor resection from the mouse models of breast cancer, and endocan levels were measured while visualizing metastatic recurrence with noninvasive luminescence imaging. In clinical settings, blood was withdrawn from 16 breast cancer patients before and after the tumor resection, and the effect of lumpectomy on blood endocan level was evaluated. Additionally, the blood endocan from 20 patients diagnosed with postoperative recurrence was measured, and their positivity rate for endocan was compared with that for serum carcinoembryonic antigen (CEA) or cancer antigen 15-3 (CA15-3).
Our preclinical and clinical experiments revealed that blood endocan levels reflected tumor burden. Furthermore, over 60% of patients suffering from postoperative recurrence who tested negative for CEA or CA15-3 were positive for endocan.
Our results support the clinical significance of endocan in breast cancer patients for detecting breast cancer recurrence.</abstract><cop>Netherlands</cop><pub>IOS Press BV</pub><pmid>39331092</pmid><doi>10.3233/CBM-240034</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1574-0153 |
| ispartof | Cancer biomarkers : section A of Disease markers, 2024-01, Vol.41 (2), p.145-154 |
| issn | 1574-0153 1875-8592 1875-8592 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11495321 |
| source | MEDLINE; Sage Journals GOLD Open Access 2024 |
| subjects | Adult Aged Animal models Animals Antigens Biomarkers Biomarkers, Tumor - blood Blood Blood levels Breast cancer Breast Neoplasms - blood Breast Neoplasms - diagnosis Breast Neoplasms - pathology Breast Neoplasms - surgery Carcinoembryonic antigen Cell Line, Tumor Female Humans Lumpectomy Metastases Mice Middle Aged Mucin-1 - blood Neoplasm Proteins - blood Neoplasm Recurrence, Local - blood Neoplasm Recurrence, Local - diagnosis Neoplasm Recurrence, Local - pathology Proteoglycans - blood Tumor markers Tumors |
| title | Blood endocan as a biomarker for breast cancer recurrence |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T00%3A05%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Blood%20endocan%20as%20a%20biomarker%20for%20breast%20cancer%20recurrence&rft.jtitle=Cancer%20biomarkers%20:%20section%20A%20of%20Disease%20markers&rft.au=Daiki,%20Kentaro&rft.date=2024-01-01&rft.volume=41&rft.issue=2&rft.spage=145&rft.epage=154&rft.pages=145-154&rft.issn=1574-0153&rft.eissn=1875-8592&rft_id=info:doi/10.3233/CBM-240034&rft_dat=%3Cproquest_pubme%3E3110407768%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3115482986&rft_id=info:pmid/39331092&rfr_iscdi=true |